Product Description
p53 Antibody | 61-402 | ProSci
Host: Rabbit
Reactivity: Human
Homology: N/A
Immunogen: This p53 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 364-393 amino acids from human p53.
Research Area: Cancer, Cell Cycle, Signal Transduction,
Tested Application: WB, IHC-P
Application: For WB starting dilution is: 1:2000
For IHC-P starting dilution is: 1:100
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: 44 kDa
Validation: N/A
Isoform: N/A
Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Clonality: Polyclonal
Clone: N/A
Isotype: Rabbit Ig
Conjugate: Unconjugated
Physical State: Liquid
Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.
Concentration: batch dependent
Storage Condition: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Alternate Name: Cellular tumor antigen p53, Antigen NY-CO-13, Phosphoprotein p53, Tumor suppressor p53, TP53, P53
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: Tumor protein p53, a nuclear protein, plays an essential role in the regulation of cell cycle, specifically in the transition from G0 to G1. It is found in very low levels in normal cells, however, in a variety of transformed cell lines, it is expressed in high amounts, and believed to contribute to transformation and malignancy. P53 is subject to modification by conjugation of SUMO-1. A p53 mutant deficient for MDM2 binding is poorly sumoylated in vivo compared to wild-type p53. Overexpression of MDM2 increases the level of p53 sumoylation, which is further stimulated by expression of ARF. These results show that p53 sumoylation is regulated by MDM2- and ARF-mediated nucleolar targeting.